Nogapendekin Alfa on Muck Rack

Nogapendekin Alfa

As seen in: ONCOLOGY journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Nogapendekin

Contact Nogapendekin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

BCMA-Directed Bispecific Antibodies Navigating a New Era in Relapsed/Refractory Multiple Myeloma

|
By FDA Approves Nivolumab, Nogapendekin Alfa, Roman Fabbricatore
| ONCOLOGY journal Verified
The treatment landscape for multiple myeloma has undergone a rapid evolution, shifting from traditional therapies to highly targeted immunotherapies that have significantly improved patient outcomes. At the 67th American Society of Hematology Annual Meeting and Exposition, a panel of experts convened for an Around the Practice® discussion, hosted by CancerNetwork, to explore the practical integration of BCMA-directed bispecific antibodies into clinical care.
Open in Who Shared Issue with article?

Inherited Drivers of Thrombocytosis: Platelet PRS as RCC Survival Marker

|
By FDA Approves Nivolumab, Nogapendekin Alfa, Roman Fabbricatore
| ONCOLOGY journal Verified
At the 2026 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, Pablo Barrios, MD, and Mustafa Saleh, MD, presented groundbreaking data linking inherited genetics to clinical outcomes in renal cell carcinoma (RCC). Their study, which utilized the STITCH pipeline to impute germline DNA from tumor sequencing in a cohort of 495 patients, identified a germline platelet polygenic risk score (PRS) as a significant predictor of overall survival.
Open in Who Shared Issue with article?

Defining Molecular Pathways Across Neuroendocrine Disease States

|
By Nogapendekin Alfa, Dapeng Wu, FDA Approves Nivolumab
| ONCOLOGY journal Verified
The Neuroendocrine Tumor Research Foundation (NETRF) continues to catalyze transformative research through its annual grant awards, supporting investigators who are dismantling the traditional boundaries of neuroendocrine tumor (NET) management.
Open in Who Shared Issue with article?
See all 5 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified